Cargando…
Efficacy of CalliSpheres® microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis
OBJECTIVE: CalliSpheres® is a microsphere that is already widely used for primary liver cancer treatment; however, its application in colorectal cancer liver metastasis (CRLM) is limited. The current study aimed to investigate the efficacy of CalliSpheres® drug-eluting bead (DEB) transarterial chemo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568812/ https://www.ncbi.nlm.nih.gov/pubmed/37828491 http://dx.doi.org/10.1186/s12885-023-11350-y |
_version_ | 1785119430611566592 |
---|---|
author | Li, Haitao Zhang, Xiaolin Zhao, Wenjiang Cai, Fei Qin, Jia Tian, Jie |
author_facet | Li, Haitao Zhang, Xiaolin Zhao, Wenjiang Cai, Fei Qin, Jia Tian, Jie |
author_sort | Li, Haitao |
collection | PubMed |
description | OBJECTIVE: CalliSpheres® is a microsphere that is already widely used for primary liver cancer treatment; however, its application in colorectal cancer liver metastasis (CRLM) is limited. The current study aimed to investigate the efficacy of CalliSpheres® drug-eluting bead (DEB) transarterial chemoembolization (TACE) therapy versus (vs.) conventional cTACE therapy in treating refractory CRLM (RCRLM) patients. METHODS: Twenty-two RCRLM patients who underwent CalliSpheres® DEB-TACE therapy (n = 11) or cTACE therapy (n = 11) were retrospectively analyzed. Data on clinical response, progression-free survival (PFS) and overall survival (OS) were retrieved. RESULTS: The objective response rate (36.4% vs. 18.2%, P = 0.338) and disease control rate (81.8% vs. 54.4%, P = 0.170) were both numerically (but not statistically) higher in the DEB-TACE group than in the cTACE group. Meanwhile, PFS was prolonged in the DEB-TACE group compared with the cTACE group [median: 12.0 (95% CI: 5.6–18.4) vs. 4.0 (95% CI: 0.9–7.1) months, P = 0.018]; OS was also longer in the DEB-TACE group compared with the cTACE group [median: 24.0 (95% CI: 18.3–29.7) vs. 14.0 (95% CI: 7.1–20.9) months, P = 0.040]. In addition, after adjustment by multivariate Cox analyses, DEB-TACE was superior to cTACE independently regarding PFS (HR: 0.110, 95% CI: 0.026–0.463, P = 0.003) and OS (HR: 0.126, 95% CI: 0.028–0.559, P = 0.006). CONCLUSION: CalliSpheres® DEB-TACE therapy may prolong survival profile than cTACE therapy in RCRLM patients, while further validation is still needed. |
format | Online Article Text |
id | pubmed-10568812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105688122023-10-13 Efficacy of CalliSpheres® microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis Li, Haitao Zhang, Xiaolin Zhao, Wenjiang Cai, Fei Qin, Jia Tian, Jie BMC Cancer Research OBJECTIVE: CalliSpheres® is a microsphere that is already widely used for primary liver cancer treatment; however, its application in colorectal cancer liver metastasis (CRLM) is limited. The current study aimed to investigate the efficacy of CalliSpheres® drug-eluting bead (DEB) transarterial chemoembolization (TACE) therapy versus (vs.) conventional cTACE therapy in treating refractory CRLM (RCRLM) patients. METHODS: Twenty-two RCRLM patients who underwent CalliSpheres® DEB-TACE therapy (n = 11) or cTACE therapy (n = 11) were retrospectively analyzed. Data on clinical response, progression-free survival (PFS) and overall survival (OS) were retrieved. RESULTS: The objective response rate (36.4% vs. 18.2%, P = 0.338) and disease control rate (81.8% vs. 54.4%, P = 0.170) were both numerically (but not statistically) higher in the DEB-TACE group than in the cTACE group. Meanwhile, PFS was prolonged in the DEB-TACE group compared with the cTACE group [median: 12.0 (95% CI: 5.6–18.4) vs. 4.0 (95% CI: 0.9–7.1) months, P = 0.018]; OS was also longer in the DEB-TACE group compared with the cTACE group [median: 24.0 (95% CI: 18.3–29.7) vs. 14.0 (95% CI: 7.1–20.9) months, P = 0.040]. In addition, after adjustment by multivariate Cox analyses, DEB-TACE was superior to cTACE independently regarding PFS (HR: 0.110, 95% CI: 0.026–0.463, P = 0.003) and OS (HR: 0.126, 95% CI: 0.028–0.559, P = 0.006). CONCLUSION: CalliSpheres® DEB-TACE therapy may prolong survival profile than cTACE therapy in RCRLM patients, while further validation is still needed. BioMed Central 2023-10-12 /pmc/articles/PMC10568812/ /pubmed/37828491 http://dx.doi.org/10.1186/s12885-023-11350-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Li, Haitao Zhang, Xiaolin Zhao, Wenjiang Cai, Fei Qin, Jia Tian, Jie Efficacy of CalliSpheres® microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis |
title | Efficacy of CalliSpheres® microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis |
title_full | Efficacy of CalliSpheres® microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis |
title_fullStr | Efficacy of CalliSpheres® microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis |
title_full_unstemmed | Efficacy of CalliSpheres® microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis |
title_short | Efficacy of CalliSpheres® microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis |
title_sort | efficacy of callispheres® microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568812/ https://www.ncbi.nlm.nih.gov/pubmed/37828491 http://dx.doi.org/10.1186/s12885-023-11350-y |
work_keys_str_mv | AT lihaitao efficacyofcallispheresmicrospheresversusconventionaltransarterialchemoembolizationinthetreatmentofrefractorycolorectalcancerlivermetastasis AT zhangxiaolin efficacyofcallispheresmicrospheresversusconventionaltransarterialchemoembolizationinthetreatmentofrefractorycolorectalcancerlivermetastasis AT zhaowenjiang efficacyofcallispheresmicrospheresversusconventionaltransarterialchemoembolizationinthetreatmentofrefractorycolorectalcancerlivermetastasis AT caifei efficacyofcallispheresmicrospheresversusconventionaltransarterialchemoembolizationinthetreatmentofrefractorycolorectalcancerlivermetastasis AT qinjia efficacyofcallispheresmicrospheresversusconventionaltransarterialchemoembolizationinthetreatmentofrefractorycolorectalcancerlivermetastasis AT tianjie efficacyofcallispheresmicrospheresversusconventionaltransarterialchemoembolizationinthetreatmentofrefractorycolorectalcancerlivermetastasis |